Year: 2026
Type: article
Abstract: Antibiotic-induced liver injury (AILI) is a heterogeneous subset of drug-induced liver injury (DILI) that ranges from self-limited biochemical abnormalities to acute liver failure and chronic cholestatic or autoimmune-like disease. This narrative review critically evaluates clinical and mechanistic evidence across major antibiotic classes while retaining a drug-centered structure. Human HLA associations, drug-specific T-cell responses, delayed onset, and immune-rich histology support adaptive immunity as a unifying framework for many therapeutic-dose idiosyncratic reactions. Direct evidence, however, varies by drug. Linezolid toxicity and historical high-dose intravenous tetracycline injury are better supported as non-idiosyncratic mitochondrial exceptions. Reactive metabolites, oxidative stress, transporter effects, and inflammatory stress may initiate or amplify injury, but cytotoxicity-only, lipopolysaccharide/TNF-α, animal, and organ-on-chip models do not by themselves reproduce clinical idiosyncratic AILI. In practice, management still requires phenotype classification, exclusion of competing causes, structured causality assessment, prompt withdrawal when feasible, severity-based referral, and avoidance of rechallenge. Biomarkers, pharmacogenomics, patient-specific models, microphysiological systems, and artificial intelligence remain investigational and require validation in adjudicated antibiotic-exposed cohorts with tolerant controls.
Source: Scientific Reviews
Authors: Jiaying Lyu, Xiaokai Guo, Yujian Fan, Yisheng He
Institution: Chinese University of Hong Kong, Shenzhen
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Keywords: antibiotic-induced liver injury, drug-induced liver injury, idiosyncratic drug reactions, adaptive immunity, HLA association, T cell response, tetracycline toxicity, mitochondrial toxicity, reactive metabolites, oxidative stress, drug transporters, cholestatic liver injury, acute liver failure, causality assessment, pharmacogenomics, biomarkers
Open Access status: hybrid
Awards: G9001398445, G95184703
OpenAlex ID: W7236689355
